As investors pile into psychedelics, idealism gives way to pharma eco
Sunday, 4 February 2024
Money is pouring into the psychedelic medicine industry, with dozens of startups vying to sell mind-expanding drugs like magic mushrooms and ayahuasca. Wall Street's exuberance for hallucinogens has rankled advocates, who fear that these drugs will become expensive, specialty medications controlled by a handful of biotech companies rather than being widely available for mental health.
|
||||
|
|
||||
You Might Like |
||||
